We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
I can't believe that after a run-up like we've seen last week that there is no mention of ENDV on SI. We ended the week up a few hundred percent and I as read it have a lot more to go.
The volume had not really increased much over the week and they will be presenting their data at a conference tomorrow (Tues March 7th) and at a Cardiology conference on March 13th. In my estimation, the run-up should see some profit taking from some long-term holders but then the run should continue to the end of the day in anticipation of tomorrow's meeting.
The two products that are in the pipeline could potentially eliminate the vast majority of cardiac bypasses performed in the US. The market is a 1-2 billion dollar market and ENDV themselves estimate 200-500 million in revenue by 2002 and 2005, respectively. One of their products is purported to decrease the restenosis (failure) rate of angioplasties to low single digits where it is 40% at present.
These two products sound great... we'll see what the company has to say tomorrow.... but come on... you gotta notice this puppy.
This ought to be great fun to trade ! ENDV... Nicotine cures cardiovascular heart disease. Just got worldwide rights from Stanford.. The Sharks are here & smelling blood & it isn't theirs LOL... I'm trading this one for fun & profit.
Funny how this board has no new posts recently. To get good info on ENDV, check out the raging bull bulletin board. There are many good posters on that board. (Of course, there are bad ones too.) A good one is Skivrmt. He is in the medical field and has a good understanding of the company. YD
From time to time I will answer questions relating to information already released by the Company. I am acting in the interest of the Company in protecting the shareholders from rumor, innuendo, and just flat lies posted by short-sellers, momentum traders, day traders and ax grinders and possibly real or potential competitors. As I have a equity in the Company and an interest its forward growth, I will post under my own name.
I will not however, respond to name-calling, denigration, slander, and the usual character assassination used by anonymous posters for self-aggrandizement.
If you are willing, I am willing to give truth a chance and enter into an honest non-privileged dialog about Endovasc and its technology
It is fairly unorthodox for a CEO to appear in a public forum, but I welcome your input.
Specifically, there is discussion on a message board other than this one regarding your previous collaborative efforts with Bard. However, there has been no news coming out of this relationship, and many fear it has fallen apart. Could you discuss your current dealing with Bard, and where we might expect this to lead?
Also, and on a related topic, many are very interested in your progress in the biodegradable stent market. Would you be so kind as to give a brief description of your product, its maturity in testing, when we might expect it on the market, and most importantly, its targeted applications?
The Bard relationship has not fallen apart, far from it. We are continually discussing various product development schemes, including peripheral stents and grafts. Bard is just slow, but eventually do make up their minds. I would expect their minds are about made up to go ahead with the next level of development. This could lead into an R&D partnership, equity investment, or various other potential.
We recently announced that we have received a patent for a biodegradable stent. The degradable stent differs from the metal stents as it is resorbed by the body after placement. As it is being resorbed, it can release various medicinal agents to the vessel wall which can range from anti-restenotics to anti-caner agents. At this time, our main efforts have been to perfect the Liprostin(tm) medicinal coatings on metal stents of "others" (which elute therapeutic levels of prostaglandin e-1) to inhibit smooth muscle cell (SMC) encroachment into the stent lumen, and to antagonize various plasma elements from stent adherence, ie, platelets, fibrin and thrombin, etc., to the stent body.
But as you suggested, the biodegradable stent market is the next window of opportunity and holds enormous market potential. We feel we have a significant edge in this development with our patented "field of use" of PGE-1 (which by-the-way is probably the potent SMC antimitogenic available) which patents its use in the field of post-angioplasty dysfunctions. I expect to have the biodegradable stent in animals next year. In the meantime, watch the take-off of "coated" metal stents which are ready for animal trials.